Introduction
============

Although it has a low morbidity rate, pancreatic cancer (PC) is one of the most fatal malignant tumor types, with the highest mortality rate worldwide ([@b1-ol-0-0-9350]). Nearly all patients with PC succumb to the disease within 1--2 years ([@b2-ol-0-0-9350]). Following pancreaticoduodenectomy (Whipple procedure), the 5-year survival rate is 25--30% for node-negative ([@b3-ol-0-0-9350]) and 10% for node-positive ([@b4-ol-0-0-9350]) diseases. The majority of patients are diagnosed at an advanced stage, owing to a lack of effective diagnostic techniques for PC diagnosis at the early stages of disease ([@b5-ol-0-0-9350]). The traditional tumor serum markers, carcinoembryonic antigen and carbohydrate antigen 19-9, are neither sensitive nor specific for screening patients with PC ([@b6-ol-0-0-9350],[@b7-ol-0-0-9350]). A number of environmental factors, including alcohol consumption, smoking history, body mass index, diabetes history and family history of PC have been demonstrated to be high-risk factors for PC ([@b8-ol-0-0-9350],[@b9-ol-0-0-9350]). However, certain individuals exposed to these risk factors do not develop PC, which suggests that genetic factors may also influence cancer progression.

The xeroderma pigmentosum group C (XPC) gene is located at chromosome 3p25 ([@b10-ol-0-0-9350]); it contains 16 exons and 15 introns, and encodes a protein of 940 amino acids ([@b11-ol-0-0-9350]). The encoded protein is an indispensable component in the early stages of global genome nucleotide excision repair (NER), particularly in the damage recognition and initiation of NER ([@b12-ol-0-0-9350]); it is involved in initiating protein complex formation and repair of these complexes ([@b13-ol-0-0-9350],[@b14-ol-0-0-9350]). There are \>687 single nucleotide polymorphisms (SNPs) in the XPC gene, with \>100 SNPs in the coding regions (<http://www.ncbi.nlm.nih.gov/projects/SNP>). However, to date, only a small number of correlation analysis studies have focused on XPC polymorphisms and PC risk. There are three polymorphisms most frequently detected in the XPC gene: poly AT insertion/deletion on intron 9 (PAT), A to C substitution in exon 15 (Lys939Gln, rs2228001) and C to T substitution in exon 9 (Ala499Val, rs2228000). The PAT polymorphism has been demonstrated to confer an increased risk of PC ([@b15-ol-0-0-9350],[@b16-ol-0-0-9350]); however, an association with PC risk has not been observed for rs2228001 and rs2228000 ([@b17-ol-0-0-9350],[@b18-ol-0-0-9350]).

The use of tag-SNPs markedly improves the effectiveness of candidate gene and disease correlation analyses ([@b19-ol-0-0-9350]). Therefore, in the present study, to understand the association between XPC polymorphisms and PC susceptibility, XPC gene tag-SNPs and functional SNPs were investigated in patients with pathologically proven PC.

Materials and methods
=====================

### Study subjects

A total of 205 patients with PC, with an age range between 24 and 87 years (mean age, 63.69±11.40 years), who were treated at The Affiliated Cancer Hospital and The First Affiliated Hospital of Xinjiang Medical University (Urumqi, Xinjiang, China) between December 2007 and December 2015 were enrolled in the present study. All patients had pathologically proven PC. Among these patients, 131 cases underwent pancreaticoduodenectomy, 19 cases underwent iodine-125 seed implantation and palliative surgery (biopsy obtained during surgery), 51 cases underwent distal (combined with the spleen) pancreatectomy and 4 cases underwent fine-needle aspiration biopsy under computed tomography scan guidance.

In addition, a total of 230 non-cancer subjects, with an age range between 26 and 88 years (mean age, 63.69±11.86 years), who were admitted to The First Affiliated Hospital of Xinjiang Medical University during the same period, were recruited as a control group. These subjects had no previous history of pancreatic disease and had not been diagnosed with any malignant cancer.

All subjects recruited to this study signed informed consent forms and the study protocol was approved by the Ethical Committee of The First Affiliated Hospital of Xinjiang Medical University.

'Drinking' was defined as consuming alcohol more than once a week, continuously over a 6-month period in a lifetime. 'Smoking' was defined as accumulative smoking of \>100 cigarettes in a lifetime. The accumulative smoking amount (packets/year) indicated the smoking status according to the following formula: Accumulative smoking amount (packets/year)=mean number of cigarettes per day/20 times the number of years of smoking. The median of the accumulative smoking amount was used as the cut-off point to define mild and heavy smokers ([@b20-ol-0-0-9350]).

### Blood collection and DNA extraction

Peripheral blood (3 ml) was collected from each participant, placed in an EDTA tube and stored at −80°C within 30 min. Genomic DNA was extracted from blood samples using a DNA blood extraction kit (BioTeke, Beijing, China) according to the manufacturer\'s protocol.

### SNP selection and genotyping

SNPs were selected from the HapMap database (<https://www.genome.gov/10001688/international-hapmap-project/> HapMap Data Rel 24/Phase II, Nov08, on NCBI B36 assembly, dbSNP b126), which provided the genotype data collected from Han Chinese individuals living in Beijing. SNPs in the XPC gene were selected by combined analysis of functional SNPs and tag-SNPs from the dbSNP (<http://www.ncbi.nlm.nih.gov/SNP/>) and HapMap databases. The minor allele frequencies were \>5%, and the linkage disequilibrium (LD) coefficient r^2^ values were \>0.8. A total of 7 tag-SNPs were located, 2 of which were in the 5′-untranslated region (5′UTR) (rs2607775 and rs3731055), 3 of which were in introns (intron 5, rs3729587; intron 6, rs3731114; and intron 12, rs2470353) and another 2 of which were in exons (exon 9, rs2228000; and exon 15, rs2228001).

The 7 SNPs were detected using a SNaPshot assay (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with PCR primers designed with Primer 5 software ([@b21-ol-0-0-9350]) The primers of the SNPs were as follows: rs2228001 forward, 5′-CTGTAGTGGGGCAGCAGCAACT-3′ and reverse, 5′-AGAGGAGGGGACCAGCTCTCAA-3′; rs2470353 forward, 5′-TGCTGGGCAGGAAGAGGTACAC-3 and reverse, 5′-GACCTGGGCCTGTTTGGCTACT-3′; rs2228000 forward, 5′-CCCACTTTTCCTCCTGCTCACA-3′ and reverse, 5′-AGGACAAAGGCTGGGTCCAAGA-3′; rs3731114 forward, 5′-ACCCGCCTGCCTCTGTCCTA-3′ and reverse, 5′-TGCCAGACTGGTGGGGAGAC-3′; rs3729587 forward, 5′-GAAACTTGCCATGGCCACAGAG-3′ and reverse, 5′-AAGGGGTCCATGAGGACACACA-3′; rs2607775 forward, 5′-GTTTCCGAGCCATGTTGCTTGT-3′ and reverse, 5′-CTTTCCTGCTTCCCGCAGTTTT-3′; and rs3731055 forward, 5′-TCCGGAGATTGACGTTGCTCTT-3′ and reverse 5′-CTCAGGGCCTACGGCAAAATTC-3′. Results were analyzed using GeneMapper 4.0 software (Applied Biosystems; Thermo Fisher Scientific, Inc.). For quality control, genotyping was performed in a double-blinded manner with 5% randomly duplicated samples. Hence, reproducibility was 100%.

### Bioinformatics analysis

The functions of the XPC SNPs were predicted using the SNPinfo Web Server (<https://snpinfo.niehs.nih.gov/>). XPC expression and survival analysis in PC was evaluated using The Cancer Genome Atlas data by the online analysis tool UALCAN (<http://ualcan.path.uab.edu/analysis.html>) ([@b22-ol-0-0-9350]).

### Statistical analysis

SPSS 17.0 (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. A goodness-of-fit χ^2^ test was used to assess the Hardy-Weinberg equilibrium. Allele frequencies were assessed by χ^2^ test. Using unconditional logistic regression with adjustment for age and sex, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the relative risks of PC associated with SNP genotypes. HaploView version 4.2 (Broad Institute, Cambridge, MA, USA) was used to generate the LD plot and to assess the association between haplotypes and PC. Comparisons of all variables between cases and control subjects were performed using the online tool on the website <http://ualcan.path.uab.edu/>. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Clinical characteristics

The demographic characteristics of subjects and related risk factors are presented in [Table I](#tI-ol-0-0-9350){ref-type="table"}. According to χ^2^ tests, no significant differences in age, sex, drinking status, body mass index, diabetes history, smoking history or family history of cancer were identified between the case and control groups (P\>0.05). Heavy smokers (tobacco ≥25 packets/year) in the case group accounted for 32.0%, which was a significantly higher value compared with that in the control group (17.5%) (P=0.019).

### Association analysis of PC susceptibility

The distribution of allelic gene frequency in the 7 tag-SNP loci conformed to the Hardy-Weinberg equilibrium in the case and control groups (P\>0.05; [Table II](#tII-ol-0-0-9350){ref-type="table"}). The C allelic gene frequency of rs2470353 in patients with pathologically proven PC was significantly increased compared with that in the control group (P=0.003). Compared with the GG gene type, PC risk was significantly increased in subjects with the variant allele C (GC and GC+CC; P=0.012 and P=0.006, respectively). The G allelic gene frequency of rs2607775 was significantly increased in patients with PC compared with that in the control group (P=0.003). Compared with the CC gene type, PC risk was significantly increased in subjects with the variant allele G (CG and CG+GG; P=0.013 and P=0.005; [Table III](#tIII-ol-0-0-9350){ref-type="table"}). The distribution of gene type and allelic gene frequency in the other 5 tag-SNP loci were not significantly different between the case and control groups (P\>0.05; [Tables II](#tII-ol-0-0-9350){ref-type="table"} and [III](#tIII-ol-0-0-9350){ref-type="table"}).

### Function prediction and expression analysis

The XPC SNP functions were predicted using the SNPinfo Web Server (<https://snpinfo.niehs.nih.gov/>). rs2470353 was identified to be located in the region of intron 12, but was not predicted to be a functional SNP. rs2607775 was located in the transcription factor binding site (TFBS) of the 5′UTR of XPC. Therefore, rs2607775 was predicted to influence XPC expression.

Since only blood samples were collected in the present study, XPC expression in pancreatic adenocarcinoma (PAAD) was analyzed using the online tool UALCAN (<http://ualcan.path.uab.edu/analysis.html>) ([@b22-ol-0-0-9350]). XPC expression was decreased in PAAD patients (P\>0.05; [Fig. 1A](#f1-ol-0-0-9350){ref-type="fig"}) irrespective of sex ([Fig. 1B](#f1-ol-0-0-9350){ref-type="fig"}), age ([Fig. 1C](#f1-ol-0-0-9350){ref-type="fig"}), cancer stage ([Fig. 1D](#f1-ol-0-0-9350){ref-type="fig"}), drinking habit ([Fig. 1E](#f1-ol-0-0-9350){ref-type="fig"}), chronic pancreatitis status ([Fig. 1F](#f1-ol-0-0-9350){ref-type="fig"}), diabetes status ([Fig. 1G](#f1-ol-0-0-9350){ref-type="fig"}) and ethnicity ([Fig. 1H](#f1-ol-0-0-9350){ref-type="fig"}), with few exceptions. Notably, XPC expression was demonstrated to be significantly decreased in Asian patients with PAAD (P=0.02; [Fig. 1H](#f1-ol-0-0-9350){ref-type="fig"}). Although a general trend of decreased XPC expression was observed in patients with PAAD, the majority of these differences were not statistically significant, potentially due to the small number of control samples (n=4) and the inevitably large individual differences in expression.

### LD and haplotype association analysis

In [Fig. 2](#f2-ol-0-0-9350){ref-type="fig"}, the range of the area surrounded by black lines indicates that 3 tag-SNPs of the XPC gene were contained in a haplotype and in a state of linkage disequilibrium. Block 1 comprised rs2228000, rs3731114 and rs3729587 ([Fig. 2](#f2-ol-0-0-9350){ref-type="fig"}). The frequencies of the haplotypes CCC and TCG were higher in patients with cancer compared with those in the non-cancer controls, and the CCC haplotype for Block 1 significantly increased the risk of PC (OR, 1.610; 95% CI, 1.035--2.481; P=0.034; [Table IV](#tIV-ol-0-0-9350){ref-type="table"}).

### Interaction analysis of smoking and XPC gene polymorphism

Compared with non-smoking subjects with wild-type GG gene in the rs2470353 locus, PC risk did not significantly increase in smoking subjects with the GC gene type (P\>0.05). PC risk increased by 3.505-fold in heavy smokers (tobacco ≥25 packets/year) with the variant allele C (OR=4.505, 95% CI=1.418--15.007, P=0.008; [Table V](#tV-ol-0-0-9350){ref-type="table"}). Compared with non-smoking subjects with wild gene type CC in the rs2607775 locus, PC risk did not increase in smoking subjects with the CC gene type (P\>0.05). PC risk increased by 3.950-fold in heavy smokers (tobacco ≥25 packets/year) with the variant allele G (CG+GG) (OR, 4.950; 95% CI, 1.758--13.924; P=0.001; [Table VI](#tVI-ol-0-0-9350){ref-type="table"}).

Discussion
==========

Previous studies have reported XPC polymorphisms to be associated with cancer risk. There are three polymorphisms most frequently detected in the XPC gene: Poly AT insertion/deletion on intron 9 (PAT), A to C substitution in exon 15 (Lys939Gln, rs2228001) and C to T substitution in exon 9 (Ala499Val, rs2228000) ([@b23-ol-0-0-9350]). Epidemiological studies have demonstrated that the PAT^+/+^ genotype results in a 1.85-fold increase in the risk of squamous cell carcinoma of the head and neck ([@b24-ol-0-0-9350]) and a 1.6-fold increase in the risk of lung cancer ([@b25-ol-0-0-9350]). Meta-analysis revealed that the exon 15 Lys939Gln (rs2228001 A\>C) C/C gene type is associated with increased risk of lung cancer and esophageal cancer ([@b26-ol-0-0-9350],[@b27-ol-0-0-9350]). The XPC Ala499Val (rs2228000, C\>T) polymorphism is associated with the risk of endometrial, colorectal and liver cancer, as well as other malignant cancer types ([@b28-ol-0-0-9350]--[@b30-ol-0-0-9350]). However, the association between other XPC polymorphisms and bladder cancer remains controversial ([@b31-ol-0-0-9350]--[@b33-ol-0-0-9350]).

In the present study, the associations between genetic polymorphisms of XPC and PC risk were investigated using a tag-SNP method. The results revealed that variant alleles at two loci were associated with increased PC risk, even though the rs2470353 locus was located in the intron area and the rs2607775 locus was located in the 5′UTR (P\<0.05). The other five tag-SNP loci, including in exon 9 (rs2228000) and exon 15 (rs222800), did not exhibit significant differences in the distribution of gene type or allelic gene frequency between the case and control groups (P\>0.05; [Tables III](#tIII-ol-0-0-9350){ref-type="table"} and [IV](#tIV-ol-0-0-9350){ref-type="table"}).

G/C polymorphisms at or near the exonic boundaries in intron 12 of the XPC gene may affect mRNA translation through exon skipping and/or aberrant mRNA folding ([@b34-ol-0-0-9350]--[@b37-ol-0-0-9350]). SNPs in the 5′UTR may affect XPC gene expression via promoter modulation ([@b34-ol-0-0-9350]), resulting in reduced DNA repair capacity (DRC) and increased risk of PC. Unfortunately, although rs2470353 is located in the region of intron 12, it is not a predicted functional SNP. rs2607775 is located on the TFBS of the 5′UTR of XPC, and is therefore predicted to influence XPC expression ([@b38-ol-0-0-9350],[@b39-ol-0-0-9350]). Furthermore, XPC expression in PAAD was analyzed using UALCAN ([@b22-ol-0-0-9350]) in the present study. XPC expression was identified to be decreased in patients with PAAD irrespective of sex, age, cancer stage, drinking habits, chronic pancreatitis status, diabetes status, or race, with few exceptions. The most notable finding was that XPC expression was decreased significantly in Asian patients with PAAD. However, due to the small number of normal control samples, the majority of these differences were not statistically significant.

SNPs in coding regions, as well as non-coding regions of the XPC gene, that are in LD with each other as part of a given haplotype may act in a collective manner to influence the phenotype. The results of the present study revealed that the CCC haplotype of rs2228000, rs3731114 and rs3729587 exhibited a higher frequency in patients with PC, compared with that in the control group, indicating that the CCC haplotype may result in an increased risk of PC. However, the exact mechanism of this remains unclear.

Smoking is recognized as a traditional risk factor for PC ([@b9-ol-0-0-9350],[@b40-ol-0-0-9350]). The present study also revealed that smoking in the XPC rs2470353 (GC+CC) and/or rs2607775 (CG+GG) subjects significantly increased PC risk. In subjects with an accumulative smoking amount of ≥25 packets/year, PC risk increased 3.505-fold with rs2470353 (GC+CC) (OR, 4.505; 95% CI, 1.418--15.007; P=0.008) and 3.950-fold with rs2607775 (CG+GG) (OR, 4.950; 95% CI, 1.758--13.924; P=0.001), indicating that the combination of mutations and smoking may serve an important role in PC progression. Smoking causes genetic damage and/or cell mutations ([@b41-ol-0-0-9350]) that may not be repaired by the NER pathway ([@b13-ol-0-0-9350],[@b14-ol-0-0-9350]), since genetic damage may not be recognized by XPC with the rs2470353 (GC+CC) and/or rs2607775 (CG+GG) mutant gene type.

The present study has initially indicated that the XPC gene rs2470353 and rs2607775 loci polymorphisms are associated with PC risk. The haplotype CCC of rs2228000, rs3731114 and rs3729587 was also identified to be associated with increased PC risk. However, additional SNP loci have been continuously selected for future study, particularly the functional loci of the exon regions and loci at splicing regions. In addition, the chromosome hereditary variation of the XPC gene and its association with PC could be further verified by transcription analysis, in order to evaluate the effects on regulation and splicing of the XPC gene.
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![(A) XPC expression in PAAD patients, (B) sex, (C) age, (D) cancer stage, (E) drinking habit, (F) chronic pancreatitis status, (G) diabetes status, and (H) patient ethnicity was analyzed using the online tool UALCAN ([@b18-ol-0-0-9350]). \*P\<0.05. XPC, xeroderma pigmentosum group C; PAAD, pancreatic adenocarcinoma; TCGA, The Cancer Genome Atlas.](ol-16-05-5631-g00){#f1-ol-0-0-9350}

![Linkage disequilibrium plot of all polymorphic sites in the XPC gene. The upper part of the figure shows 7 sites of tag-SNP in the XPC gene, while the number in the lower part is a value of 100×D' (linkage disequilibrium parameter). The standard color scheme of Haploview was used to display the strength of LD: black indicates strong LD, grey intermediate, whereas white denotes no LD. r^2^ values are shown within the boxes. LD, linkage distribution; XPC, xeroderma pigmentosum group C; SNP, single nucleotide polymorphism.](ol-16-05-5631-g01){#f2-ol-0-0-9350}

###### 

General characteristics of the pancreatic cancer cases (n=205) and controls (n=230).

  Characteristics                                                    Cases, n (%)   Controls, n (%)   χ^2^    P-value
  ------------------------------------------------------------------ -------------- ----------------- ------- ---------
  Age, years                                                                                          0.600   0.896
    ≤49                                                              31 (15.1)      36 (15.7)                 
    50--59                                                           33 (16.1)      36 (15.7)                 
    60--69                                                           65 (31.7)      66 (28.6)                 
    ≥70                                                              76 (37.1)      92 (40.0)                 
  Sex                                                                                                 0.003   0.953
    Male                                                             126 (61.5)     142 (61.7)                
    Female                                                           79 (38.5)      88 (38.3)                 
  Diabetes                                                                                            2.330   0.127
    No                                                               135 (65.9)     167 (72.6)                
    Yes                                                              70 (34.1)      63 (27.4)                 
  BMI, kg/m^2^                                                                                        6.026   0.110
    \<18.5                                                           84 (41.0)      69 (30.0)                 
    18.5--23.9                                                       71 (34.6)      93 (40.4)                 
    24-27.9                                                          33 (16.1)      48 (20.9)                 
    ≥28                                                              17 (8.3)       20 (8.7)                  
  Smoking                                                                                             1.909   0.167
    Non-smoker                                                       105 (51.2)     133 (57.8)                
    Smoker                                                           100 (48.8)     97 (42.2)                 
  Packets/year smoked^[a](#tfn1-ol-0-0-9350){ref-type="table-fn"}^                                    5.520   0.019
    \<25                                                             68 (68.0)      80 (82.5)                 
    ≥25                                                              32 (32.0)      17 (17.5)                 
  Drinking                                                                                            0.011   0.917
    Seldom                                                           156 (76.1)     176 (76.5)                
    Often                                                            49 (23.9)      54 (23.5)                 
  Family history of cancer                                                                            2.812   0.094
    No                                                               179 (87.3)     212 (92.2)                
    Yes                                                              26 (12.7)      18 (7.8)                  

Calculated as percentage of smokers. P-values were calculated from two-sided χ^2^ tests. BMI, body mass index.

###### 

Characteristics of the 7 tag-SNPs in the XPC gene.

                                           MAF     HWE P-value                   
  ----------- ---------- ----------- ----- ------- ------------- ------- ------- -------
  rs2228001   14187449   Extron 15   A/C   0.351   0.365         0.600   0.633   0.667
  rs2470353   14190268   Intron 12   G/C   0.124   0.065         0.595   0.981   0.003
  rs2228000   14199887   Extron 9    C/T   0.305   0.300         0.728   0.300   0.876
  rs3731114   14206622   Intron 6    C/G   0.205   0.217         0.146   0.409   0.652
  rs3729587   14208625   Intron 5    G/C   0.334   0.302         0.780   0.754   0.312
  rs2607775   14220095   5′UTR       C/G   0.163   0.096         0.197   0.149   0.003
  rs3731055   14220439   5′UTR       G/A   0.232   0.241         0.697   0.348   0.740

P-values were calculated from two-sided χ^2^ tests.

P\<0.05. SNP, single nucleotide polymorphism; XPC, xeroderma pigmentosum group C; MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium; UTR, untranslated region.

###### 

Association between polymorphisms of XPC genes and pancreatic cancer.

                                    χ^2^ test               Logistic regression                           
  ----------- --------- ----- ----- ----------------------- --------------------- ----------------------- ----------------------------------------------------
  rs2228001   A/A       88    91    1.000                                         1.000                   
              A/C       90    110   0.846 (0.565--1.268)    0.418                 0.824 (0.547--1.239)    0.352
              C/C       27    29    0.963 (0.528--1.755)    0.901                 1.009 (0.548--1.857)    0.977
              A/C+C/C   117   139   0.870 (0.594--1.276)    0.477                 0.860 (0.585--1.265)    0.444
  rs2470353   G/G       158   201   1.000                                         1.000                   
              G/C       43    28    1.954 (1.162--3.285)    0.011                 1.942 (1.154--3.267)    0.012^[b](#tfn5-ol-0-0-9350){ref-type="table-fn"}^
              C/C       4     1     5.089 (0.563--45.980)   0.108                 5.253 (0.577--47.822)   0.141
              G/C+C/C   47    29    2.062 (1.241--3.425)    0.005                 2.053 (1.235--3.412)    0.006^[b](#tfn5-ol-0-0-9350){ref-type="table-fn"}^
  rs2228000   C/C       98    116   1.000                                         1.000                   
              C/T       89    90    1.171 (0.786--1.742)    0.438                 1.164 (0.780--1.737)    0.457
              T/T       18    24    0.888 (0.455--1.731)    0.727                 0.914 (0.463--1.803)    0.795
              C/T+T/T   107   114   1.111 (0.762--1.619)    0.584                 1.113 (0.762--1.626)    0.579
  rs3731114   C/C       133   143   1.000                                         1.000                   
              C/G       60    74    0.872 (0.576--1.319)    0.516                 0.848 (0.557--1.291)    0.442
              G/G       12    13    0.992 (0.437--2.252)    0.986                 1.006 (0.441--2.292)    0.989
              C/G+G/G   72    87    0.890 (0.602--1.316)    0.559                 0.885 (0.596--1.313)    0.543
  rs3729587   G/G       90    111   1.000                                         1.000                   
              G/C       93    99    1.159 (0.779--1.723)    0.467                 1.132 (0.759--1.689)    0.543
              C/C       22    20    1.357 (0.697--2.641)    0.369                 1.392 (0.711--2.726)    0.335
              G/C+C/C   115   119   1.192 (0.817--1.740)    0.363                 1.184 (0.810--1.732)    0.383
  rs2607775   C/C       146   190   1.000                                         1.000                   
              C/G       51    36    1.844 (1.143--2.974)    0.011                 1.839 (1.139--2.970)    0.013^[b](#tfn5-ol-0-0-9350){ref-type="table-fn"}^
              G/G       8     4     2.603 (0.769--8.811)    0.112                 2.500 (0.733--8.522)    0.143
              C/G+G/G   59    40    1.920 (1.217--3.028)    0.005                 1.914 (1.212--3.024)    0.005^[b](#tfn5-ol-0-0-9350){ref-type="table-fn"}^
  rs3731055   G/G       122   135   1.000                                         1.000                   
              G/A       71    79    0.995 (0.664--1.489)    0.979                 0.981 (0.655--1.471)    0.928
              A/A       12    16    0.830 (0.378--1.824)    0.642                 0.830 (0.377--1.829)    0.644
              G/A+A/A   83    95    0.967 (0.659--1.418)    0.863                 0.965 (0.657--1.417)    0.856

P-value, OR and 95% CI were calculated by unconditional logistic regression analysis adjusted for age and sex.

P\<0.05. SNP, single nucleotide polymorphism; XPC, xeroderma pigmentosum group C; CI, confidence interval.

###### 

XPC haplotype of rs2228000, rs3731114 and rs3729587 frequencies and associations with pancreatic cancer risk.

  Haplotype   Freq    Cases (freq)   Controls (freq)   OR (95% CI)            P-value
  ----------- ------- -------------- ----------------- ---------------------- ----------------------------------------------------
  CGC         0.208   0.201          0.217             0.928 (0.667--1.285)   0.646
  CCC         0.106   0.129          0.082             1.610 (1.035--2.481)   0.034^[a](#tfn7-ol-0-0-9350){ref-type="table-fn"}^
  TCG         0.299   0.301          0.297             1.021 (0.765--1.367)   0.887
  CCG         0.384   0.365          0.401             0.863 (0.651--1.127)   0.276

P-values are calculated by χ^2^ test. The case/control omnibus test is a H-1 degree of freedom test, if there are H haplotypes.

P\<0.05. XPC, xeroderma pigmentosum group C; OR, odd ratio; CI, confidence interval; Freq, frequency.

###### 

Risk of XPC genotypes at rs2470353 with pancreatic cancer by smoking status.

  Genotype   Smoking status, pack-years   Cases, n   Controls, n   OR (95% CI)             P-value
  ---------- ---------------------------- ---------- ------------- ----------------------- ----------------------------------------------------
  GG         Non-smoker                   83         115           1.000                   
             \<25                         56         73            1.041 (0.598--1.635)    0.724
             ≥25                          19         13            2.071 (0.967--4.431)    0.082
  GC+CC      Non-smoker                   22         18            1.683 (0.846--3.345)    0.096
             \<25                         12         7             2.366 (0.891--6.278)    0.076
             ≥25                          13         4             4.505 (1.418--15.007)   0.008^[a](#tfn9-ol-0-0-9350){ref-type="table-fn"}^

P-values were calculated by unconditional logistic regression analysis adjusted for age and sex.

P\<0.05. XPC, xeroderma pigmentosum group C; OR, odds ratio; CI, confidence interval.

###### 

Risk of XPC genotypes at rs2607775 with pancreatic cancer by smoking status.

  Genotype   Smoking status, pack-years   Cases, n   Controls, n   OR (95% CI)             P-value
  ---------- ---------------------------- ---------- ------------- ----------------------- -----------------------------------------------------
  CC         Non-smoker                   77         106           1.000                   
             \<25                         55         72            1.047 (0.661--1.658)    0.831
             ≥25                          14         12            1.503 (0.668--3.376)    0.288
  CG+GG      Non-smoker                   28         27            1.414 (0.771--2.595)    0.270
             \<25                         13         8             2.251 (0.891--5.759)    0.089
             ≥25                          18         5             4.950 (1.758--13.924)   0.001^[a](#tfn11-ol-0-0-9350){ref-type="table-fn"}^

P-values were calculated by unconditional logistic regression analysis adjusted for age and sex.

P\<0.05. XPC, xeroderma pigmentosum group C; OR, odds ratio; CI, confidence interval.

[^1]: Contributed equally
